Working to make the promise of precision medicine a reality
P. Ron Ellis
Chief Executive Officer/President
P. Ron Ellis is one of our founders and has served as our president and chief executive officer since 1996 and as a member of our Board of Directors since 1995. Prior to joining Endocyte, Mr. Ellis was with Hill-Rom Company, the $1.2 billion healthcare division of Hillenbrand Industries. While at Hill-Rom, he held a variety of senior management positions, including vice president of strategy/corporate development and vice president of the specialty care division. Mr. Ellis holds a BS in computer science and an MBA from Brigham Young University, and a certification in regulatory affairs from Purdue University.
Mike A. Sherman
Chief Operating Officer and Chief Financial Officer
Mike A. Sherman has been appointed to the newly created position of Chief Operating Officer. Mr. Sherman has served as our chief financial officer since 2006. Previously, Mr. Sherman served in various executive roles, most recently as vice president of finance and strategic planning of Guidant Corporation, a cardiovascular device manufacturer acquired by Boston Scientific Corporation, a medical device company. Mr. Sherman holds a BA in economics from DePauw University and an MBA from the Tuck School of Business at Dartmouth. He also serves on the Board of Directors at Mead Johnson Nutrition, and the Indianapolis Children’s Museum Board of Trustees.
Philip S. Low, PhD
Chief Science Officer
Dr. Philip S. Low is one of our founders and has served as our chief science officer since 1998 and as a member of our Board of Directors since 1995. Dr. Low has served on the faculty at Purdue University since August 1976, where he is currently the Ralph C. Corley Distinguished Professor of Chemistry. He holds a BS in chemistry from Brigham Young University and a PhD in biochemistry from the University of California, San Diego.
Alison Armour, M.B., Ch.B., B.Sc., M.Sc., M.D., MRCP., FRCR
Chief Medical Officer
Dr. Armour joined the company as chief medical officer in August 2015. Prior to joining Endocyte, Dr. Armour served as vice president of oncology at Novartis and GSK, where she led the global strategic TYKERB development team in breast cancer and was accountable for a large matrix team composed of clinical, medical, regulatory, statistics, medical affairs, science and commercial colleagues based in multiple sites in the US, UK and Japan. Prior to Novartis and GSK, she was the global medical science director at AstraZeneca and led the development and approval of IRESSA, the first EGFR RTKi registered in first line EGFR mutation positive non-small cell lung cancer. Before joining industry, Dr. Armour established herself as a thought leader in medical and radiation oncology. Dr. Armour holds her B.Sc. in biochemistry, M.B., Ch.B. MSc, and Doctorate of Medicine from the University of Glasgow, MRCP at the Member of the Royal College of Physicians Glasgow, and her FRCR at the Royal College of Radiologists London, UK.
Michael A. Brinkley
Vice President of Quality
Michael Brinkley has served as vice president of quality since June 2013. From January 2012 to June 2013, Mr. Brinkley served as director of quality for Endocyte. Prior to joining Endocyte, Mr. Brinkley spent 30 years in the pharmaceutical industry in analytical chemistry, microbiology, and quality assurance. Mr. Brinkley holds a BS in microbiology from North Carolina State University and an MBA from the University of North Carolina, Chapel Hill.
Vice President of Marketing & Communications
Matthew Call joined Endocyte in 2003 as director of business development and has served as vice president of business development since 2012. He is responsible for all strategic partnering and licensing transactions. Mr. Call has led numerous successful partnering processes, including Endocyte’s transformational billion-dollar partnership with Merck for vintafolide. Prior to joining Endocyte, Mr. Call spent several years working in business development in information technology, where he structured and managed strategic relationships with firms such as Hewlett-Packard, General Electric, First Data Corporation, and Disney. He received a BA from Brigham Young University and an MBA from Purdue University.
Scot L. Harper, PhD
Vice President of Clinical Operations
Scot L. Harper, Ph.D., joined the company as vice president of clinical operations in May 2013. Previously, he was vice president of clinical operations at Novartis and senior director of clinical operations at Eli Lilly and Company. He also served as oncology medical director for Lilly’s US affiliate. Dr. Harper received his doctorate in medical physiology from Indiana University School of Medicine and an MBA from the University of South Alabama, where he served on the faculty of the College of Medicine. He received his undergraduate degree from DePauw University.
Christopher P. Leamon, PhD
Vice President of Research & Development
Dr. Christopher P. Leamon has served as our vice president of research and development since 2000. From 1999 to 2000, Dr. Leamon served as our director of biology and biochemistry. Prior to joining us, Dr. Leamon was employed in the pharmaceutical industry where he conducted discovery research in the field of peptide, oligonucleotide, liposome, and DNA drug delivery for Glaxo Wellcome, a healthcare company, and Isis Pharmaceuticals, a biomedical pharmaceutical company. He holds a BS in chemistry from Baldwin Wallace College and a PhD in biochemistry from Purdue University.
P. David Mozley, M.D.
Vice President, Imaging
Dr. Mozley joined the company as vice president of imaging in April 2015. Prior to joining Endocyte, Dr. Mozley served as professor and chief of the Division of Nuclear Medicine at Weill Cornell Medical College and the New York Presbyterian Hospital/Weill Cornell Campus in Manhattan. He was also the medical director of the Medical College’s Citigroup Biomedical Imaging Center, a member of the Weill Cornell Radiation Safety Committee, and a chair of an Institutional Review Board. From 2001 to 2012, Dr. Mozley held multiple positions with progressively increasing responsibilities at Eli Lilly and Merck & Co. While at Merck & Co., he served as senior imaging lead across therapeutic areas for mega-multi-center trials that used imaging as a major endpoint, chaired the PhRMA Imaging group, and co-chaired a technical committee on quantitative imaging for the Radiological Society of North America. Dr. Mozley received his B.S. at the College of William & Mary, Williamsburg, VA, his M.D. from the Brody School of Medicine at East Carolina University, and then trained at the University of Pennsylvania in Philadelphia, where he was promoted to associate professor of radiology. He has contributed to the publication of over 100 research reports in the literature on imaging, most of which focused on methods of quantification.
Katherine K. Parker
Vice President, Human Resources
Katherine Parker joined Endocyte in 2013 and serves as the vice president of human resources. Prior to joining Endocyte, Ms. Parker served in various entrepreneurial and executive roles such as vice president of human resources and administrative services for Hyundai Motor America, the North American headquarters for Hyundai Automotive Group. She holds a BA in history from the University of California, Los Angeles and an MBA from California State University. Ms. Parker also serves on the Board of Directors at West Lafayette Schools Education Foundation and Wabash Center.
Iontcho Vlahov, PhD
Vice President of Discovery Chemistry
Dr. Iontcho Vlahov joined Endocyte in 1999 and serves as the vice president of discovery chemistry. He received his PhD in synthetic organic and structural chemistry from Ruhr University, Bochum, Germany. Before joining Endocyte, he was the head of discovery chemistry at Ivax Corp in Miami, Florida. Prior to that, he held various positions, including visiting scientist at Hercules, Inc.; senior research scientist at the University of Konstanz, Germany; research scientist at the Institute of Organic Chemistry, Bulgarian Academy of Sciences; and research associate at the University of Iowa. Dr. Vlahov is an Alexander von Humboldt Fellow and has published more than 55 scientific articles and 15 patents. His main interest is the synthesis of complex biologically active molecules and the design of novel organic reactions. Currently, Dr. Vlahov’s research is committed to the discovery and development of novel conjugates ensuring intracellular release of folate-targeted chemotherapeutic agents.